stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Revenue growth
BioNTech SE Sponsored ADR's revenue growth over the twelve months to 30 September 2026 was −22.7%, down 31.8 percentage points from fiscal 2025 (9.07%). Over the past ten years it has ranged from −77.3% (fiscal 2023) to 3,975.0% (fiscal 2021); the current reading is higher than 67% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 9.07% | 37.05 |
| FY2024 | −28.0% | 49.36 |
| FY2023 | −77.3% | (58.58) |
| FY2022 | −18.8% | (3,993.71) |
| FY2021 | 3,975.0% | 3,621.93 |
| FY2020 | 353.0% | 372.30 |
| FY2019 | −19.3% | (137.64) |
| FY2018 | 118.4% | 172.56 |
| FY2017 | −54.2% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −16.4% | 42.11 |
| Jun 2026 | −58.5% | (30.31) |
| Mar 2026 | −28.2% | (5.87) |
| Dec 2025 | −22.4% | (52.06) |
| 24 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. compare | 240.0% |
| BBIO BridgeBio Pharma, Inc. compare | 167.3% |
| ASND Ascendis Pharma A/S compare | 126.0% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 56.2% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 22.3% |
| EXEL Exelixis, Inc. compare | 9.12% |
| BNTX BioNTech SE Sponsored ADR | −22.7% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Beneish M-score
- The full statement